Monopar Therapeutics Inc (MNPR) Quote

MNPR 1 yr

MNPR: And yet MORE news today, about a "Wilson Disease" license agreement ---
https://finance.yahoo.com/news/monopar-therapeutics-secures-license-wilson-113132036.html

how can someone find stocks that run like this?

went to new HIGH 38.50

crazy crazy day

MNPR pic.twitter.com/kC0pGrS2Fh— THE FINAL COUNTDOWN (@THIS_TIME_X) October 24, 2024

MNPR.................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

In at $24 out at $38 this round thanks trading gods

Hit that low floater lol 2m float $24.06 

HALT Again

Timber

MNPR: Monster CONGRATS to ya!! WOW!!

29.74 halt down after hitting 36.35

now thats the TOP gainer of the day

28.14 make that 13 halt$

12 haltz https://www.nasdaqtrader.com/trader.aspx?id=tradehalts

MNPR 25.58 halted up again

was just halted up 20.49

MARKET MADNE$$

continues....

MNPR.............................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

MNPR...................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

MNPR YTD

Looking good

MNPR...............................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

You’re welcome. May take some time, but these are certainly not small-time players.

Regardless, if they’ve got a better way to treat people with illnesses, that’s a win-win.

Hi Dell. That is some great DD you did and I thank you for letting me know. I have never even bought this stock, I just reported the news but now I will be looking for dips to possibly take at least a small starters position. Hope you are doing well and please stay in touch :)😍

Good info. Just checked this out today. Pretty damn impressive group of execs - CEO and COO went to Stanford. COO has a long history, including selling off companies he was CEO of to major players.

Bought a little high and was looking to flip, but I think I’m going to hold this one.

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans.

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase plasminogen activator receptor (uPAR). These include a majority of all triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

A total-body positron emission tomography (PET) image was taken at 168 hours (7 days) post administration of MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) of the first cancer patient in the trial with one of the known high uPAR-expressing cancer types. The results, seen in Figure 1, demonstrate the specificity, durability, and uptake of MNPR-101-Zr in the metastatic tumors relative to normal tissue. The regions of higher uptake also align with the locations of the previously observed metastatic tumors on conventional FDG PET imaging.

https://ml.globenewswire.com/Resource/Download/cda29080-7e74-46b0-8b93-5925a209f2ab/2024-9-11-pr-figure-1-jpeg.jpg

“This is exactly what we had hoped to see – highly preferential uptake in the tumor,” said Andrew Cittadine, Monopar’s Chief Operating Officer.

MNPR-101-Zr was evaluated against FDG, the gold standard for detecting metastatic tumors. Figure 2 shows FDG uptake in its highest-uptake tumor compared to MNPR-101-Zr uptake in the same tumor imaged on the same Siemens Biograph Vision Quadra™ PET/CT scanner.

https://ml.globenewswire.com/Resource/Download/cb0b4c63-91dc-46e1-a3c5-862ccc4251d8/2024-9-11-pr-figure-2-jpeg.jpg

“At the Melbourne Theranostic Innovation Centre, we utilize one of the world's most sensitive PET/CT scanners. Using the same scanner for FDG and MNPR-101-Zr, the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation,” said Professor Rodney Hicks, MBBS(Hons), MD, FRACP, FICIS, FAAHMS, lead investigator on the MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial.

Monopar recently received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial [link] which is currently scheduled to launch in the fourth quarter of this calendar year.

“We are looking forward to sharing additional data at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024, where our abstract has been accepted as a 'Top-Rated Oral Presentation' within the Scientific Program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Further information about the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

About Monopar Therapeutics Inc.

Monopar?Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include: the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation; and that an MNPR-101-Lu Phase 1 therapeutic clinic

$5.30 and 6.75 on high side and then $2.95- $4 is where most of the action will
Play out

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

MNPR.............................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

MNPR.........................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

On August 21, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.

who killed the radiostar?
looking very great down here

Stock up 50% recently. Quietly moving higher.
They will report some data soon. Running in anticipation?
I like this stock a lot.
I think it has more to go.
JMO

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173913331

MNPR................................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783

MNPR: And let alone try to explain that sudden (late-day) circa 240% soaring by @OCEA!!! And when one searches iHub's "ALL POSTS" about OCEA, one gets ambiguous posts about "Reddit was all over it", & "One guy threw $300,000 at it". BOY, that sure explains it all!!! (BONKERS STUFF, Bro!!)

If there really is 15 million shares OS...That could explain the run...Granted it is a Day 2 on a Friday,the Run fizzled

Wow it just crashed....idk what's next

Gamma squeeze

Still strong

MNPR: So am I, Dude!! NOTHING anymore makes any reasonable sense at all!!! (Their cheap FLUFF "news" of yesterday --- a mere Pre-Clinical Cancer stuff routine --- was patently UN-impressive at its core!! Yet today it soars!!)

Off to a bad Start...surprised there isn't any posters,on this board...Some wild moves in either direction

#MNPR 🔥 gap fill to $2-$3 coming? Big upside! $MNPR

How many shares OS?

A lot of dumping

Spring tight ready for 1.5

Yup keeps popping off trend line

MNPR: You yourself have posted this sentiment countless times, Boss!!! NONE of this 'Wall Street' stuff makes ANY (rational) sense at all!!!

yep and still goin

MNPR: The obvious WINNER of this day!!! (And all behind a mere PHASE-1 Cancer study routine!!! How the fluck can anyone call this stuff???!!!)

Level 2 just switched bullish

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

MNPR: WOW!! I hear-ya behind ALL of those notes, Boss!!! (And heck, I wouldn't mind being YOUR son --- his favorite 'WHEELS' is that red VET, no doubt??? Or, he's already FLIPPED a stock by himself, & bought his OWN Vet??? Naturally!!!)